Compare AAL & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAL | TWST |
|---|---|---|
| Founded | 1930 | 2013 |
| Country | United States | United States |
| Employees | 133700 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.2B |
| IPO Year | 2004 | 2018 |
| Metric | AAL | TWST |
|---|---|---|
| Price | $12.99 | $163.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 8 |
| Target Price | $15.59 | ★ $46.88 |
| AVG Volume (30 Days) | ★ 60.3M | 1.6M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,633,000,000.00 | $376,572,000.00 |
| Revenue This Year | $12.17 | $18.91 |
| Revenue Next Year | $4.62 | $15.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.78 | ★ 20.32 |
| 52 Week Low | $10.09 | $23.30 |
| 52 Week High | $18.79 | $163.70 |
| Indicator | AAL | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 70.79 |
| Support Level | $11.97 | $39.81 |
| Resistance Level | $13.37 | N/A |
| Average True Range (ATR) | 0.32 | 8.92 |
| MACD | 0.06 | 1.47 |
| Stochastic Oscillator | 44.13 | 94.55 |
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Dallas/Fort Worth, Charlotte, Chicago, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest average fleet of US legacy carriers.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.